|Market Size in 2022
|Market Forecast in 2030
|CAGR (in %)
|USD 48 Million
|USD 78 Million
Huber Needles Market
The global Huber needle market size was worth around USD 48 million in 2022 and is predicted to grow to around USD 78 million by 2030 with a compound annual growth rate (CAGR) of roughly 6.15% between 2023 and 2030.
The report delves deeper into several crucial aspects of the global Huber needle industry. It includes a detailed discussion of existing growth factors and restraints. Future growth opportunities and challenges that impact the Huber needle market are comprehensively addressed in the report.
Huber needles are medical devices that are used in various medical procedures. They have specifically been used for processes involving long-term venous access. This method is used for delivering medication or drawing blood along with other aspects such as pumping nutrition or blood products in a patient's bloodstream over time including weeks, months, or years.
Huber needles have claimed higher importance in the medical community as primary and crucial devices since they are used extensively for accessing implanted vascular access devices (VADs) which include catheters that are inserted peripherally and tunnel catheters or implantable ports. VADs allow medical professionals long-term access to a patient's bloodstream so that they can conduct regular administration of drugs such as intravenous (IV) antibiotics. Huber needles are non-coring right-angle needles and the market for these medical devices is likely to grow at a steady rate.
The growing rate of chemotherapy sessions to drive market expansion
The global Huber needles market is expected to grow due to the increasing number of cancer patients across the globe and the rising rate of chemotherapy sessions. In such procedures, Huber needles, owing to their specific design, are used along with chemotherapy ports. Since the needle is extremely long and has a beveled tip, it can easily pass through the skin and the silicone septum which is a part of the reservoir of the implanted port.
Huber needles have proven to be extremely helpful across infusion-related medical activities including antibiotics administration, dialysis, blood transfusions, and administration of saline fluids. They can be left in one spot in the body for many hours or days and hence allow more comfort to the patients as they do not have to worry about removing the unit for every visit to the medical facility.
The World Health Organization (WHO) claims that cancer is currently a leading cause of death globally. In 2021, nearly 1.91 million new cases of cancer were diagnosed across the world and each year, around 1.12 million cancer patients undergo chemotherapy along with other forms of radiation. In addition to this, the growing number of patients diagnosed with other forms of deadly diseases that require extensive and long-term medical care could further trigger the demand for Huber needles. Factors such as the rise in cancer-treatment aid and the development of new cancer-treating drugs are also essential to the market.
Concerns surrounding the overall safety of the needles to restrict market expansion
The Huber needle industry may register restricted growth due to the growing discussions and concerns around the overall safety of needles. For instance, a report on the National Library of Medicine pointed out that the curved Huber needles could lead to additional lesions of the pump membrane or the port.
The report also suggested that the re-sterilization of Huber needles is not recommended since it is impossible to safely sterilize the small lumina of the needle. Moreover, there is also an option to use regular needles for accessing the port. However, they cannot be used when the patient is undergoing a Computed Tomography Scan.
Growing investment in global healthcare infrastructure to provide growth opportunities
The global Huber needle market is expected to come across several growth opportunities due to the increasing investment toward improving global healthcare infrastructure and providing essential or primary medical care to all. For instance, in June 2023, the National Cancer Institute (NCI) announced the launch of a new, large, and precision medicine cancer initiative which will test the result of new drug combinations used for treating children and adults.
Similarly in June 2022, the current US government announced a new model to improve cancer care in the country. The announcement was made in association with the Centers for Medicare & Medicaid Services (CMS) and the U.S. Department of Health and Human Services. Other factors such as increasing innovation in terms of medical procedures using Huber needles may help in generating more revenue.
Contamination risk using Huber needles to challenge further expansion
Huber needles like other medical devices are prone to contamination if not used correctly. Since these needles are injected deep into the skin, they are at a higher risk of contamination. In addition to this, the lack of skilled medical professionals using Huber needles further adds to the complication.
A recent report highlighted the importance of being extra careful while using the Huber needle. It concludes that more than 49% of needlestick injuries caused by Huber needle was when the device was being withdrawn from the patient. Many companies are working toward reducing injuries inflicted by such incidents but nonetheless, they continue to challenge the market players operating in the global Huber needle industry.
The global Huber needle market is segmented based on application, product type, end-user, and region.
Based on application, the global market is segmented into lap-band adjustments, dialysis, IV cancer application, home parenteral nutrition, blood transfusions, and others. The highest growth was observed in the IV cancer application segment where these needles are used extensively for IV therapies and cancer-related chemotherapy.
Growing research toward advanced cancer care along with a rising number of hospitals offering cancer treatment along with increased funding by government and private companies to encourage low-income families to undergo such treatment contributes to higher segmental growth. The US government spent nearly USD 190.1 billion on cancer care in 2015.
Based on product type, the global market divisions are straight Huber needles and curved Huber needles. The former segment was the leading revenue generator in 2022. These needles showcase a right-angle cannula and hence allow more accurate and risk-free insertion.
Curve Huber needles have a slight curve at the top and can be riskier if not handled with care. However, they have specific applications, especially in cases where the straight variant cannot be used. As per general recommendation, patients with thin-walled chests can be treated using 1 inch Huber needle while the dimension may change to 1.5 inches in the case of thick-walled chests.
Based on end-users, the Huber needle industry is divided into ambulatory services, hospitals & clinics, home care settings, oncology centers, and others. The highest growth rate was in the hospitals & clinics segment followed by the oncology center segment. This is mainly due to the high influx of patients in hospital settings and regular or more frequent medical activities requiring the use of Huber needles. Oncology centers across the globe are best for cancer treatment but the number of such units is highly restricted. India has around 27 government-recognized cancer centers.
|Huber Needles Market Research Report
|Market Size in 2022
|USD 48 Million
|Market Forecast in 2030
|USD 78 Million
|CAGR of 6.15%
|Number of Pages
|Key Companies Covered
|AngioDynamics Inc., Becton, Dickinson and Company (BD), B. Braun Melsungen AG, Nipro Medical Corporation, Smiths Medical, Medtronic plc, Baxter International Inc., Orientmed International Holding Limited, Teleflex Incorporated, Cook Medical Inc., Terumo Corporation, Infusion Setters Healthcare Inc., Vygon Group, Argon Medical Devices Inc., Amecath Medical Technologies and many more.
|By Application, By Product Type, By End-Users, and By Region
|North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
|2017 to 2021
|2023 - 2030
|Avail customized purchase options to meet your exact research needs. Request For Customization
North America to continue its growth trajectory during forecast timeline
The global Huber needle market is expected to be led by North America during the forecast period mainly due to the presence of a robust medical infrastructure in addition to the US being one of the most prominent nations for treating severe forms of cancer. As of 2022, the country registered nearly 18.05 million cancer survivors.
In addition to this, the US Food & Drugs Administration department has approved the use of Huber needles for medical procedures which has assisted in promoting the adoption of these medical devices across the country.
Access to healthcare, the presence of medical reimbursement policies, and a preventive care approach are crucial for North America's growth. Europe is the second-largest user of Huber needles as the regional population is registering a growing number of patients with medical conditions requiring extensive medical care. More than 1.7 million England citizens have been diagnosed with chronic kidney disease (CKD) and studies indicate that nearly 1 million people are living with the condition in an undiagnosed state.
The global Huber needle market is led by players like:
By Product Type
Huber needles are medical devices that are used in various medical procedures. They have specifically been used for processes involving long-term venous access.
The global Huber needles market is expected to grow due to the increasing number of cancer patients across the globe and the rising rate of chemotherapy sessions.
According to study, the global Huber needle market size was worth around USD 48 million in 2022 and is predicted to grow to around USD 78 million by 2030.
The CAGR value of the Huber needle market is expected to be around 6.15% during 2023-2030.
The global Huber needle market is expected to be led by North America during the forecast period mainly due to the presence of a robust medical infrastructure in addition to the US being one of the most prominent nations for treating severe forms of cancer.
The global Huber needle market is led by players like AngioDynamics, Inc., Becton, Dickinson and Company (BD), B. Braun Melsungen AG, Nipro Medical Corporation, Smiths Medical, Medtronic plc, Baxter International Inc., Orientmed International Holding Limited, Teleflex Incorporated, Cook Medical Inc., Terumo Corporation, Infusion Setters Healthcare Inc., Vygon Group, Argon Medical Devices, Inc., Amecath Medical Technologies and many more.